Ann: Change of Director's Interest Notice - Mr Andrew Grant, page-31

ImpediMed's Sozo Installation Growth in Focus — Market TalkSep 10, 202409:21 GMT+10IPD−6.52%ImpediMed needs to show an acceleration in installations of its Sozo device, which allows monitoring of heart-failure patients at home, signals Canaccord Genuity. That's because ImpediMed's cash pile is shrinking. An operating cash outflow of A$17.8 million in FY 2024 means it began the current fiscal year with A$24.6 million in cash. "Our key focus from here remains on the timing to new installed base growth, with sharp focus on whether current cash can sustain the 6-9 month sales cycle once more payor additions come through," analyst Elyse Shapiro says. CG moves to "speculative buy," from "buy," on ImpediMed and lowers its price target by 36%, to A$0.09/share. ImpediMed ended Monday at A$0.046. ([email protected]; @dwinningWSJ)

targeted hit job.

"monitoring of heart failure patients at home" tells you all you need to know.